Novo Drops NovoSeven Stroke Program Following Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk announced Feb. 26 that it would not seek approval for use of NovoSeven (human recombinant factor VIIa) in intracerebral hemorrhage following negative efficacy findings in a Phase III study.
You may also be interested in...
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Sanofi Pentacel Revised Action Date Is Nov. 2
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.